Aurora trades up about 20% on the TSX and Nasdaq after Organigram agreed to acquire it for C$7.80 per share, a deal valuing Aurora at about C$561 million.
Investorideas.com (www.investorideas.com newswire) a go-to platform for big investing ideas, including cannabis stocks issues a news and trading alert for Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB).
The stock makes the TSX top gainerlist following acquisition news. Aurora is trading at 7.10 +1.21 (+20.54%) on volume of over 1.7 Million shares. The stock has a day’s high of $7.20.
Aurora is trading at 5.08 +0.86 (+20.24%) on the Nasdaq.
Highlights
- Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity
- Offer represents a 93% premium to Aurora’s Unaffected Share Price on August 10, 2026 1 and a 21% premium to the implied value of the unsolicited Curaleaf Hostile Bid as of November 2, 2026 2 , unanimously rejected by Aurora’s Board of Directors
- Organigram shareholders to participate alongside Aurora shareholders in a company with greater scale, enhanced supply chain certainty, global footprint and diversification
- The combined company will own and operate five EU-GMP certified production and distribution facilities and bring world-class innovation to existing and new markets to meet international demand and support global market share expansion
- This Transaction has unanimous support of both Organigram and Aurora Boards of Directors; Organigram’s and Aurora’s directors and senior officers and Organigram’s significant shareholder have each entered into voting support agreements
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI)) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) today announced that they have entered into an arrangement agreement (the ” Arrangement Agreement “) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the ” Aurora Shares “) of Aurora at a price of C$7.80 per Aurora Common Share (the ” Transaction “).
The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (” Curaleaf “) of its intention to launch a hostile takeover bid for Aurora (the ” Unaffected Price “), and a 21% premium relative to the current bid value of the Curaleaf hostile offer 3 (the ” Hostile Bid “) as most recently amended on October 6, 2026, which was unanimously rejected by Aurora’s Board of Directors.
The Transaction provides Aurora shareholders with compelling immediate value, meaningful choice in how they receive their consideration, and the opportunity for continued participation in the future growth and value creation of the combined company.
Together, Organigram and Aurora will create a global cannabis champion with a leadership position in Canada, Europe and Australia and a growing presence across other key regions. The two Canadian-headquartered cannabis companies will boast a global platform with greater scale, broader capabilities, financial strength and international reach. Organigram’s recreational cannabis leadership, production network, R&D platform and European medical commercial operations complement Aurora’s global medical cannabis leadership, established international presence, and EU-GMP certified manufacturing capabilities. The combined company will also benefit from the support of Organigram’s cornerstone strategic shareholder, BT DE Investments Inc., a wholly-owned indirect subsidiary of British American Tobacco (” BAT “), a global consumer goods company with demonstrable innovation, marketing and product development capabilities around the world.
“This Transaction is a defining step in Organigram’s strategy to build a disciplined, global cannabis leader,” said James Yamanaka, CEO of Organigram. “By bringing together Aurora’s established global medical cannabis platform with our Canadian operations and growing international footprint, we are creating a larger, stronger, and more diversified company. We are excited to build on our complementary operations, expertise, capital resources, and cultures to accelerate growth, meet the growing global demand, and drive long-term profitable growth.”
“Combining with Organigram will accelerate Aurora’s international growth strategy by strengthening commercial execution, expanding our product and R&D capabilities, and extending our global operating network,” said Miguel Martin, Executive Chairman and CEO of Aurora. “For Aurora’s shareholders, the Transaction is the result of a robust strategic review process and delivers compelling value today, meaningful choice in how they receive it and the opportunity to participate in the future of a leading cannabis company.”
Research cannabis stocks at Investorideas.com
Learn about becoming a featured stock
https://www.investorideas.com/marijuana-stocks/stocks_list.asp
Disclaimer/Disclosure: Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published/created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer and disclosure info: https://www.investorideas.com/about/disclaimer.asp
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/about/private_policy.asp
Disclaimer / Disclosure: InvestorIdeas.com is a digital publisher of financial content and is not a registered investment adviser or broker-dealer. This article is informational and is not a recommendation to buy or sell any security; some content may be sponsored or compensated. See our full disclaimer.
